NEWS
PRESS CENTER
2022
2022-05-01
- In January, we received IND approval for Phase I/II combination therapy of LAE002 with sintilimab, targeting patients with solid tumors with prior PD-1/PD-L1 treatments from NMPA in China
- In March, we received IND approval for Phase II LAE002 and LAE001 combination study in patients with mCRPC in South Korea
- In April, we completed Series D financing
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy
